Shanta M. Zimmer, MD

Articles by Shanta M. Zimmer, MD

Economic Model for Emergency Use Authorization of Intravenous Peramivir

ByBruce Y. Lee, MD, MBA,Julie H. Y. Tai, MD,Rachel R. Bailey, MPH,Sarah M. McGlone, MPH,Ann E. Wiringa, MPH,Shanta M. Zimmer, MD,Kenneth J. Smith, MD, MS,Richard K. Zimmerman, MD, MPH

March 10th 2011

The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.

Economic Model for Emergency Use Authorization of Intravenous Peramivir

ByBruce Y. Lee, MD, MBA,Julie H. Y. Tai, MD,Rachel R. Bailey, MPH,Sarah M. McGlone, MPH,Ann E. Wiringa, MPH,Shanta M. Zimmer, MD,Kenneth J. Smith, MD, MS,Richard K. Zimmerman, MD, MPH

January 14th 2011

The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.

Latest Updated Articles

Economic Model for Emergency Use Authorization of Intravenous Peramivir
March 10th 2011
Economic Model for Emergency Use Authorization of Intravenous Peramivir
January 14th 2011

Shanta M. Zimmer, MD

Articles by Shanta M. Zimmer, MD

Economic Model for Emergency Use Authorization of Intravenous Peramivir

Economic Model for Emergency Use Authorization of Intravenous Peramivir

Latest Updated Articles

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access